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Shc homology 2–containing inositol 59 phosphatase-2
(SHIP2) is a lipid phosphatase that inhibits insulin signaling
downstream of phosphatidylinositol 3-kinase (PI3K); its role
in vascular function is poorly understood. To examine its
role in endothelial cell (EC) biology, we generatedmice with
catalytic inactivation of one SHIP2 allele selectively in ECs
(ECSHIP2D/+).Hyperinsulinemic-euglycemicclampingstud-
ies revealed that ECSHIP2D/+ was resistant to insulin-
stimulated glucose uptake in adipose tissue and skeletal
muscle comparedwith littermatecontrols. ECs fromECSHIP2D/+
mice had increased basal expression and activation of
PI3K downstream targets, including Akt and endothelial
nitric oxide synthase, although incremental activation by
insulin and shear stress was impaired. Insulin-mediated
vasodilation was blunted in ECSHIP2D/+ mice, as was aor-
tic nitric oxide bioavailability. Acetylcholine-induced vaso-
dilation was also impaired in ECSHIP2D/+ mice, which was
exaggerated in the presence of a superoxide dismutase/
catalase mimetic. Superoxide abundance was elevated in
ECSHIP2D/+ ECs and was suppressed by PI3K and NADPH
oxidase 2 inhibitors. These ﬁndings were phenocopied in
healthy human ECs after SHIP2 silencing. Our data suggest
that endothelial SHIP2 is required tomaintain normal systemic
glucose homeostasis and prevent oxidative stress-induced
endothelial dysfunction.
Insulin resistance is a pathophysiological hallmark of
obesity and type 2 diabetes (1). When systemic (2,3), or
endothelium-restricted (4,5), insulin resistance leads to an
unfavorable imbalance between endothelial cell (EC) gener-
ation of the signaling radical nitric oxide (NO) and poten-
tially cytotoxic oxidants, such as superoxide (4,5) and hydrogen
peroxide (6). Although the effects of whole-body and cell-
speciﬁc insulin resistance on EC function are appreciated,
the local and systemic consequences of increased insulin
signaling in ECs are less well characterized. To address
this, we generated mice with endothelium-restricted inhibi-
tion of Shc homology 2–containing inositol 59 phosphatase
2 (SHIP2). SHIP2 is a lipid phosphatase that catalyzes the
removal of the 59 phosphate group from phosphatidylino-
sitol (3–5)-trisphosphate (PI[3,4,5]P3) (7). PI(3,4,5)P3 accu-
mulation promotes the activity of signaling molecules, such
as Akt; by reducing PI(3,4,5)P3 accumulation, SHIP2 acts as
a negative regulator of insulin-induced Akt signaling (7). Indeed,
transgenic mice overexpressing SHIP2 have reduced glucose
tolerance and blunted Akt activation in classic insulin target
tissues (8).
Three different murine models of SHIP2 loss of function
have been generated to examine the role of SHIP2 in insulin
signaling. Clément et al. (9) described mice with deletion of
Inppl1 (which encodes SHIP2), although these mice had
unplanned deletion of Phox2a, a transcription factor involved
in normal development. Sleeman et al. (10) studied a second
knockout mouse with deletion of Inppl1, but intact Phox2a;
this mouse also had developmental abnormalities. Recently,
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mice with catalytic inactivation of SHIP2 were generated by
inserting Cre-recombinase–speciﬁc loxP sites into introns
ﬂanking Inppl1 exons 18–19 (coding the SHIP2 catalytic
domain) (11); these mice also had substantial developmental
abnormalities, making conclusions regarding insulin sig-
naling challenging.
To improve our understanding of enhanced endothelial
insulin signaling, while circumventing the developmental im-
pact of global SHIP2 deletion, we generated mice in which the
catalytically inactive SHIP2 described above (11) is restricted to
ECs using Tie2-Cre (referred to as ECSHIP2D/+). We hypothe-
sized that endothelial SHIP2 activity is required to maintain
appropriate systemic and vascular responses to insulin.
RESEARCH DESIGN AND METHODS
Generating ECSHIP2D/+ Mice
Mice were bred onto a C57BL/6J background for .10 gen-
erations in a conventional animal facility with a 12-h light/
dark cycle. To examine the effect of chronically increased
insulin signaling, male mice that were 10 months of age
were used in all experiments, unless stated otherwise, con-
ducted in accordance with accepted standards of humane
animal care under UK Home Ofﬁce project license 40/3523.
A catalytically inactive SHIP2 mutant mouse was generated
by inserting Cre recombinase–speciﬁc loxP sites into intronic
regions ﬂanking exons 18–19 of the Inppl1 gene (11); mice
with one ﬂoxed allele (SHIP2(18,19)/+) were crossed with
Tie2-Cre mice (The Jackson Laboratory) to produce progeny
with germline endothelium–speciﬁc SHIP2 inactivation (re-
ferred to as ECSHIP2D/+). Cre-positive SHIP2+/+ littermates
were controls in all experiments.
Metabolic Tests
Glucose and insulin tolerance tests were performed by blood
sampling after intraperitoneal injection of glucose (1 mg/g)
or recombinant human insulin (0.75 unit/kg: ACTRAPID;
Novo Nordisk), respectively, as previously described (4,5).
Glucose concentrations were determined in whole blood
using a portable meter (Roche). Plasma insulin concentra-
tions were determined by ELISA (CrystalChem). Free fatty
acids and triglycerides were measured in fasting plasma
using colorimetric assays (Abcam) (12).
In Vivo Hyperinsulinemic-Euglycemic Clamp Studies
In vivo euglycemic insulin clamps were performed at the
Mouse Metabolic Phenotyping Center at Vanderbilt Uni-
versity (Nashville, TN), as previously described (13). These
use tracer techniques to assess the following: 1) whole-body
insulin sensitivity; 2) insulin suppression of endogenous
(i.e., hepatic) glucose production; and 3) rates of individual
tissue glucose uptake.
Experimental Protocol
Mice were maintained on a chow diet (Diet 7012; Teklad).
Catheters were implanted in a carotid artery for blood
sampling and in a jugular vein for infusions 5 days before
the study. On the morning of each study, food was removed
and clamps were initiated after a 5-h fast. One hundred
twenty minutes (t = 2120 min) prior to initiation of the
clamps, animals received a bolus (1.5 mCi) followed by a
continuous (0.075 mCi/min) infusion of [3-3H]glucose.
Baseline blood or plasma parameters were determined in
blood samples collected at210 and 0 min. At t = 0, an insulin
infusion (4 mU/kg/min) was started, the infusion rate of
[3-3H]glucose was increased (0.15 mCi/min), and a constant
infusion of heparinized saline washed with erythrocytes
from donor animals (5.5 mL/min) were administered to
prevent a fall in hematocrit. These infusions were continued
for the duration of the clamp (145 min). The blood glucose
concentration was clamped at ;100–110 mg/dL using a
variable glucose infusion rate (GIR). Blood glucose was mon-
itored every 10 min to validate clamping, and the GIR was
adjusted accordingly. Blood was taken at between 80 and
120 min for the determination of [3-3H]glucose. Clamp in-
sulin was determined at t = 120 and 145 min. At 120 min,
13 mCi of 2[14C]deoxyglucose ([14C]2DG) was administered
as an intravenous bolus. Blood was taken at between
122 and 145 min for the determination of [14C]2DG. After
the last sample, mice were euthanized and tissue samples
were collected.
Plasma and Muscle Sample Analysis
Immunoreactive insulin was assayed with a rat radioimmu-
noassay kit (Millipore). To measure plasma 3-[3H]-D-glucose,
the sample was deproteinized with barium hydroxide
(Ba[OH]2) and zinc sulfate (ZnSO4), dried, and radioactivity
determined using liquid scintillation counting. Excised so-
leus, gastrocnemius, superﬁcial vastus lateralis, and gonadal
adipose tissue were deproteinized with percholoric acid and
then neutralized to approximately pH 7.5. A portion of the
extract was counted ([2-14C]DG and [2-14C]DG-G-phosphate
([2-14C]DGP) and a portion treated with Ba(OH)2 and
ZnSO4 and the supernatant was counted ([2-
14C]DG).
Both [2-14C]DG and [2-14C]DGP radioactivity levels were
determined using liquid scintillation counting.
Studies of Vasomotor Function in Aortic Rings
Vasomotor function was assessed ex vivo in aortic rings as
previously described (2–5). Rings were mounted in an organ
bath containing Krebs-Henseleit buffer (composition [in
mmol/L]: NaCl 119, KCl 4.7, KH2PO4 1.18, NaHCO3 25,
MgSO4 1.19, CaCl2 2.5, and glucose 11.0) and gassed with
95% O2/5% CO2. Rings were equilibrated at a resting ten-
sion of 3g for 45 min. A cumulative dose response to the
constrictor phenylephrine (PE) (1 nmol/L to 10 mmol/L)
was performed. Vasodilation to insulin was assessed with
incremental doses of ACTRAPID insulin (0.1–1,000 mU/mL)
in aortic segments preconstricted maximally with PE.
Relaxation responses to cumulative addition of acetylcho-
line (1 nmol/L to 10 mmol/L) and sodium nitroprusside
(0.1 nmol/L to 1 mmol/L) were performed. The effects of
MnTmPyP (10 mmol/L for 30 min; Calbiochem) on aortic
relaxation were examined, as previously reported (2). Relax-
ation responses are expressed as the percentage decrement
in preconstricted tension. Bioavailable NO in aortic segments
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subject to isometric tension was measured by recording the
increase in tension elicited by NG-monomethyl-L-arginine
(L-NMMA) (0.1 mmol/L) in aortic segments maximally pre-
constricted with PE.
Amplex Red Assay for Hydrogen Peroxide in Aorta
H2O2 was measured using an Amplex Red Hydrogen Perox-
ide/Peroxidase Assay Kit (Thermo Fisher Scientiﬁc), according
to the manufacturer protocol. Freshly harvested aortae
were collected into modiﬁed Krebs-HEPES buffer, con-
taining 20 mmol/L HEPES, 119 mmol/L NaCl, 4.6 mmol/L
KCl, 1 mmol/L MgSO40.7H2O, 0.15 mmol/L Na2HPO4,
0.4 mmol/L KH2PO4, 5 mmol/L NaHCO3, 1.2 mmol/L
CaCl2, and 5.5 mmol/L glucose, pH 7.4. Aortas were cleaned
of adipose tissue and divided into 2-mm rings. Rings were
incubated in 50 mL of modiﬁed Krebs-HEPES buffer with
half also receiving 1,250 units/mL catalase (free from thymol)
for 1 h at 37°C. Fifty microliters of freshly prepared
100 mmol/L Amplex Red reagent with 0.2 units/mL horse-
radish peroxidase was added to samples and incubated for 1 h
at 37°C, protected from light. Rings were removed from the
samples and ﬂuorescence measured on a Varioskan plate
reader (Thermo Fisher Scientiﬁc) (excitation 530 nm, emis-
sion 590 nm). The mean reading with catalase was sub-
tracted from the mean without catalase, and this value
was plotted on a simultaneously prepared H2O2 standard
curve. Dry tissue mass was used for normalization (12).
Pulmonary EC Isolation and Culture
Primary ECs were isolated from lungs by immunoselection
with CD146 antibody–coated magnetic beads as previously
reported (4,14) and cultured in 2 mL of EGM-2-MV (Lonza)
supplemented with 5% FCS until conﬂuent. These express a
range of endothelial markers including endothelial NO syn-
thase (eNOS), Tie2, and CD102 protein (4,14).
SHIP2 Activity Assay
SHIP2 activity was measured using the 59PtdIns(3,4,5)P3
Phosphatase Activity Fluorescent Polarization Assay (Echelon
Biosciences) according to the manufacturer instructions,
using a Polarstar Optima plate reader (BMG Labtech) with
excitation at 550 nm and measuring polarized emission at
580 nm.
NO Synthase Activity in ECs
Active eNOS produces NO and L-citrulline from L-arginine
in a stoichiometric reaction. Insulin-stimulated eNOS activ-
ity in ECs was determined by the conversion of [14C]-L-
arginine to [14C]-L-citrulline as previously described (14,15).
ECs (13 106) were incubated at 37°C for 20 min in HEPES
buffer pH 7.4 as follows (in mmol/L): 10 HEPES, 145 NaCl,
5 KCl, 1 MgSO4, 10 glucose, and 1.5 CaCl2 containing
0.25% BSA. 0.5 mCi/mL [14C]-L-arginine was then added
for 5 min prior to stimulation with insulin (100 nmol/L)
for 15 min before the reaction was stopped with cold PBS
containing 5 mmol/L unlabeled L-arginine and 4 mmol/L
EDTA, after which cells were denatured in 95% ethanol.
After evaporation, the pellet was dissolved in 20 mmol/L
HEPES-Na+ (pH 5.5) and applied to a well-equilibrated
Dowex (Na+ form) column. The eluate [14C]-L-citrulline con-
tent was quantiﬁed by liquid scintillation and normalized
against total protein mass.
Exposure of ECs to Flow-Mediated Shear Stress
Pulmonary ECs were seeded onto ﬁbronectin-coated 6-well
plates. Conﬂuent monolayers were placed onto an orbital
rotating platform (Grant Instruments) inside an incubator
(16). The radius of orbit of the orbital shaker was 10 mm,
and the rotation rate was set to 210 rpm for 10 min, gen-
erating a shear force of 12 dyne/cm2.
Lucigenin Enhanced Chemiluminescence
We used lucigenin (5 mmol/L), enhanced chemilumines-
cence to measure NADPH-dependent superoxide produc-
tion in pulmonary ECs, as previously described (12). All
experiments were performed in triplicate. Pulmonary ECs
were suspended in PBS containing 5% FCS, 0.5% BSA, and
50 mmol/L Gp91ds-tat (GenScript) or scrambled ds-tat pep-
tide (GenScript) and incubated at 37°C for 30 min. Lumi-
nescence was measured upon the addition of a nonredox
cycling concentration of lucigenin (5 mmol/L) and NADPH
(100 mmol/L) using an autodispenser (Varioskan; Thermo
Fisher Scientiﬁc).
Cell Lysis, Immunoblotting, and Immunoprecipitation
Pulmonary ECs were lysed in extraction buffer containing
the following (in mmol/L, unless otherwise speciﬁed):
50 HEPES, 120 NaCl, 1 MgCl2, 1 CaCl2, 10 NaP2O7,
20 NaF, 1 EDTA, 10% glycerol, 1% NP-40, 2 sodium ortho-
vanadate, 0.5 mg/mL leupeptin, 0.2 phenylmethylsulfonyl
ﬂuoride, and 0.5 mg/mL aprotinin. Cell extracts were son-
icated in an ice bath and centrifuged for 15 min before
protein measurement using the BCA Assay (Thermo Fisher
Scientiﬁc). Equal amounts of protein were resolved on SDS-
polyacrylamide gels (Thermo Fisher Scientiﬁc) and transferred
to polyvinylidine diﬂuoride membranes. Immunoblotting
was carried out with primary antibodies produced by Cell
Signaling Technologies, except for the following: mouse
NADPH oxidase 2 (NOX2), mouse insulin receptor, mouse
insulin receptor substrate (IRS) 1, mouse IRS2, and human
SHIP2 (Abcam); human NOX2 and b-actin (Santa Cruz Bio-
technology); mouse SHIP2 (gift from Stéphane Schurmans,
Université de Liège, Liège, Belgium). Blots were incubated
with appropriate peroxidase-conjugated secondary anti-
bodies and developed with enhanced chemiluminescence
(Millipore).
Lentiviral Knockdown of SHIP2 in Human Umbilical
Vein ECs
Knockdown of SHIP2 in human umbilical vein ECs (HUVECs)
(PromoCell, Heidelberg, Germany) was performed with short
hairpin RNA (shRNA) transduction using a lentivirus vector
(catalog #SHCLNV-NM001567; Sigma-Aldrich) as previously
described (17). HUVECs were transduced with a multiplicity
of infection of 10 and incubated at 37°C for 4 days prior
to analysis. Control cells were transduced with a green ﬂuo-
rescent protein–targeting control shRNA lentivirus (catalog
#SHC002H; Sigma-Aldrich).
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Gene Expression
mRNA was isolated using TRIzol (Thermo Fisher Scientiﬁc),
and SHIP2 mRNA was quantiﬁed using SYBR-Green–based
real-time quantitative PCR using (ABI Prism 7900HT; Ap-
plied Biosystems) (4). Primer details are as follows: truncated
SHIP2 forward 59-ACC-TTA-ACT-ACC-GCT-TAG-ACA-TGG-A;
truncated SHIP2 reverse 59-ATC-AGT-GCA-ACT-AAA-TCG-
AAG-GAA; nontruncated region of SHIP2 forward 59-AAG-
ACT-ACT-CGG-CGG-AAC-CA; nontruncated region of
SHIP2 reverse 59-TGC-CGA-TCA-CCC-AAC-GA; b-actin
forward 59-CGT-GAA-AAG-ATG-ACC-CAG-ATC-A; and b-actin
reverse 59-TGG-TAC-GAC-CAG-AGG-CAT-ACA-G. As pub-
lished (12), RNA was also isolated from puriﬁed CD11b+
myeloid cells to deﬁne truncated SHIP2 expression. TaqMan
(Thermo Fisher Scientiﬁc) assays were used to measure the
expression of interleukin (IL)-1b (catalog #mm00434228_m1),
IL-6 (catalog #mm00446190_m1), and tumor necrosis
factor-a (TNF-a) (catalog #mm00443258_m1) in gastrocne-
mius muscle and epididymal adipose tissue.
Flow Cytometry
Heparinized whole blood underwent erythrocyte lysis (Phar-
malyse; BD Biosciences) prior to isolation of peripheral blood
mononuclear cells by centrifugation. After blocking with CD16/
32 Fc block (BD Biosciences), cells were stained with anti-
CD45-VioBlue, anti-CD11b-FITC, and anti-Ly6G-PE (all from
Miltenyi Biotec); and Ly6C-APC (eBioscience). Paired samples
were prepared with corresponding isotype-speciﬁc controls. Flow
cytometry (LSRFortessa; BD Biosciences) was performed to deﬁne
the following subsets: total leukocytes (CD45+); myeloid cells
(CD45+CD11b+); monocytes (CD45+CD11b+Ly6G2Ly6C+);
neutrophils (CD45+CD11b+Ly6Ghi2Ly6Chi); “inﬂammatory”
monocytes (CD45+CD11b+Ly6G2Ly6Chi); “patrolling” mono-
cytes (CD45+CD11b+Ly6G2Ly6Clo). All populations are
expressed as the number of cells per milliliter blood.
Cytokine ELISA
Serum IL-6 and TNF-a were measured with commercially




Epididymal fat ﬁxed in 4% paraformaldehyde was embed-
ded in parafﬁn blocks and 5-mm sections stained with Sirius
Red (Sigma-Aldrich) to demarcate collagen deposition,
which is a feature of inﬂammation (18). The percentage
of the Sirius Red staining area was calculated with ImageJ
(National Institutes of Health).
Adipose Vascularity
Epididymal fat ﬁxed in 1% paraformaldehyde then stained
with LipidTOX Green (Thermo Fisher Scientiﬁc) and isolectin-
B4-Alexa647 (Thermo Fisher Scientiﬁc) was whole mounted
in chamber slides and imaged with a confocal microscope
(catalog #LSM880; Zeiss). The vascular (isolectin-B4) per-
centage area was calculated in thresholded 4-mm maximum
intensity projections using ImageJ (National Institutes of
Health).
Skeletal Muscle Vascularity
Gastrocnemius muscle ﬁxed in 4% paraformaldehyde was
embedded in Tissue-Tek O.C.T. compound (Sakura) and snap
frozen. The 5-mm cryosections were stained with isolectin-
B4-Alexa Fluor 647 (Thermo Fisher Scientiﬁc) and DAPI
(Southern Biotech) then imaged with a confocal microscope
(catalog #LSM880; Zeiss). The percentage of vascular area
(isolectin-B4) was calculated in thresholded 2-mm maxi-
mum intensity projections using ImageJ (National Insti-
tutes of Health).
Statistics
Results are expressed as the mean (SEM). Comparisons
within groups were made using paired Student t tests and
between groups using unpaired Student t tests or repeated-
measures ANOVA, as appropriate. P , 0.05 was considered
to be statistically signiﬁcant.
RESULTS
Basic Characterization of Mice With Endothelium-
Speciﬁc Inactivation of SHIP2
To examine the effect of reducing the restraining role of
SHIP2 on insulin action speciﬁcally in the endothelium, we
generated mice with Tie2-Cre–mediated catalytic inactiva-
tion of one SHIP2 allele (ECSHIP2D/+). ECSHIP2D/+ mice were
born with the same frequency as control littermates. There was
no difference in gross appearance (Fig. 1A), organ weight (Fig.
1B), or body length (Fig. 1C) when comparing ECSHIP2D/+
and control mice, although 10-month-old ECSHIP2D/+ mice
were slightly heavier (Fig. 1D). We quantiﬁed truncated
SHIP2 mRNA in organs with differing vascularity; as
expected, SHIP2D18–19 mRNA was only detectable above
nonspeciﬁc ﬂuorescence in ECSHIP2D/+ organs, not control
organs (Fig. 1E). SHIP2D18–19 mRNA was also undetectable
in non-ECs from ECSHIP2D/+ lungs (Fig. 1F) but was just
detectable in CD11b+ myeloid cells (.3,000-fold lower than
ECSHIP2D/+ pulmonary EC, and ;5-fold above nonspeciﬁc
ﬂuorescence) (Supplementary Fig. 1A). Endothelial SHIP2
protein expression was mildly reduced in ECSHIP2D/+
mice (Fig. 1G), whereas SHIP2 activity was substantially
reduced (Fig. 1H), which is in keeping with targeted cata-
lytic domain deletion, as shown previously in work using
SHIP2(18,19)/+ mice (11).
ECSHIP2D/+ Mice Do Not Exhibit a Proinﬂammatory
State
As very low-level expression of truncated SHIP2 was found
in myeloid cells, we conducted a detailed assessment of
systemic and tissue-speciﬁc inﬂammation. Flow cytometry
revealed no difference in circulating leukocyte populations
(Supplementary Fig. 1B), and leukocyte SHIP2 activity was
comparable in ECSHIP2D/+ and control littermates (Supple-
mentary Fig. 1C). ECSHIP2D/+ mice had normal serum lev-
els of TNF-a and IL-6 (Supplementary Fig. 1D and E) along
with normal expression of TNF-a, IL-1b, and IL-6 in white
adipose tissue and skeletal muscle (Supplementary Fig. 1F).
We found no evidence of altered adipose tissue inﬂammation
using Sirius Red collagen staining (Supplementary Fig. 1G).
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ECSHIP2D/+ Mice Have Reduced Glucose Tolerance
and Insulin Sensitivity
Compared with control littermates, ECSHIP2D/+ mice had higher
fasting glucose concentrations (Fig. 2A), similar fasting
insulin concentrations (Fig. 2B), and higher HOMA-insulin
resistance (Fig. 2C). ECSHIP2D/+ mice had delayed normal-
ization in capillary glucose during glucose tolerance testing
(Fig. 2D), but insulin tolerance test results were similar to
Figure 1—Basic characterization of ECSHIP2D/+ mice. Compared with control Cre+ littermate controls, no difference was seen in the gross
development of ECSHIP2D/+ mice (A); ECSHIP2D/+ organ weights were comparable (n $7) (B); the nose-to-tail length of ECSHIP2D/+ mice was
similar (n $4) (C); ECSHIP2D/+ mice were slightly heavier (n $6) (D); truncated SHIP2 mRNA was detectable in organs from ECSHIP2D/+ mice,
but not controls (n = 3) (E); truncated SHIP2 mRNA was detectable only in ECs from ECSHIP2D/+ lungs and not in the non-EC fraction (n = 3) (F);
SHIP2 protein expression (representativeWestern blot shown above the panel) wasmildly reduced in ECs fromECSHIP2D/+ mice (n$5) (G); and SHIP2
activity was substantially reduced in ECs from ECSHIP2D/+ mice (n $9) (H). AU, arbitrary units; PEC, pulmonary EC. *P < 0.05.
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those in control littermates (Fig. 2E). Levels of serum free
fatty acids (Fig. 2F) and triglycerides (Fig. 2G) were not al-
tered in ECSHIP2D/+ mice. In hyperinsulinemic-euglycemic
clamp studies, ECSHIP2D/+ mice required ;25% less glu-
cose to maintain euglycemia than controls (Fig. 3A). In tracer
studies, glucose uptake into adipose tissue and skeletal mus-
cle was reduced (Fig. 3B), whereas hepatic glucose output
was no different between ECSHIP2D/+ mice and controls
(Fig. 3C and D).
ECs From ECSHIP2D/+ Mice Have Increased Basal
Activation of Signaling Molecules Downstream of
Phosphatidylinositol 3-Kinase, Although Incremental
Activation by Insulin and Shear Stress Is Impaired
In the endothelium, phosphatidylinositol 3-kinase
(PI3K) transduces insulin signaling by catalyzing the
addition of a phosphate group to the 39 position of
inositol rings, generating 39-phosphoinositides, including
PI(3,4,5)P3, which by activating phosphoinositide-dependent
kinase-1 (PDK1) activates the serine/threonine kinase Akt/
PKB (19). Akt activates downstream signaling molecules
including eNOS (20). ECSHIP2D/+ had increased basal ex-
pression of total PDK1 and phosphorylated (p) PDK1, total
Akt, and T308 pAkt, total eNOS, and S1177 peNOS, Ric-
tor (which phosphorylates Akt at S473), and pRictor
(Fig. 4A). Importantly, 6-week-old ECSHIP2D/+ mice had
normal endothelial total Akt, Rictor, and eNOS expres-
sion and normal adipose tissue and skeletal muscle vas-
cularity (Supplementary Fig. 2), suggesting that adulthood
signaling abnormalities do not reﬂect persistent develop-
mental abnormalities. ECSHIP2D/+ had comparable insu-
lin-stimulated induction of Akt S473 phosphorylation but
diminished downstream induction of eNOS S1177
phosphorylation compared with controls (Fig. 4B).
PI3K/Akt also mediate shear-induced eNOS activation in
ECs; ECSHIP2D/+ ECs exhibited no increase in the phos-
phorylation of Akt S473 or eNOS S1177 in response to
shear stress (Fig. 4C). Notably, we found no signiﬁcant dif-
ferences in basal or insulin-stimulated phosphorylation of
the insulin receptor or insulin receptor substrates 1/2 (Sup-
plementary Fig. 3).
Figure 2—Abnormal glucose homeostasis in ECSHIP2D/+ mice. A: Fasting glucose was increased in ECSHIP2D/+ mice (n = 7). B: Fasting insulin in
ECSHIP2D/+ mice was comparable to that of controls (n $6). C: HOMA-insulin resistance (IR) was increased in ECSHIP2D/+ mice (n $12). D:
Glucose tolerance was impaired in ECSHIP2D/+ mice (n $8). E: Insulin tolerance testing was similar in ECSHIP2D/+ mice vs. controls (n $8). F:
Serum free fatty acid (FFA) levels were similar in ECSHIP2D/+ mice vs. controls (n $6). G: Serum triglyceride levels were similar in ECSHIP2D/+
mice vs. controls (n $6). *P < 0.05.
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ECSHIP2D/+ Mice Have Blunted Acetylcholine- and
Insulin-Mediated Aortic Vasodilation Associated With
Vascular Oxidative Stress
Ex vivo aortic vasomotor responses were studied in an organ
bath apparatus. Consistent with our ﬁndings in ECs, ECSHIP2D/+
mice had blunted insulin-mediated vasodilation (Fig. 5A).
ECSHIP2D/+ mice exhibited signiﬁcantly less constriction
to the nonselective NOS inhibitor L-NMMA (Fig. 5B–D),
which is indicative of reduced NO biogenesis in response
to isometric tension. There was subtle impairment of ace-
tylcholine-induced relaxation in ECSHIP2D/+ mice (Fig. 5E),
but sodium nitroprusside responses were comparable to
those of controls (Fig. 5F). To explore whether vasodilating
oxidants were masking more substantial impairment of
acetylcholine-mediated vasodilation in ECSHIP2D/+ mice, we
repeated acetylcholine relaxation studies in the presence of
the superoxide dismutase/catalase mimetic MnTmPyP.
MnTmPyP reduced acetylcholine-mediated aortic relaxa-
tion in ECSHIP2D/+ and control vessels, but the extent
of inhibition was signiﬁcantly greater in ECSHIP2D/+ vessels
(Fig. 5G–K). Hydrogen peroxide, the more stable product of
superoxide dismutation, was also elevated in ECSHIP2D/+
aortae (Fig. 5L). In isolated lung ECs, superoxide abundance
was increased, as assessed by lucigenin-enhanced chemilu-
minescence and with dihydroethidium ﬂuorescence (Fig.
6A). Superoxide is generated by many enzymes, and we
have shown that Nox2 NADPH oxidase is a critical patho-
physiological source of superoxide in models of global in-
sulin resistance (4,5). In ECSHIP2D/+ ECs, Nox2 protein
expression was increased (Fig. 6B). Moreover, superoxide
abundance was normalized with the Nox2-speciﬁc inhibitor
Gp91ds-tat (Fig. 6C) and the PI3K inhibitors Wortmannin
and LY294002 (Fig. 6D). Oxidative stress is often associated
with reduced eNOS activity, and this was conﬁrmed in ECSHIP2D/+
ECs treated with insulin (Fig. 6E).
SHIP2 Knockdown in Human ECs Phenocopies
the Signaling Abnormalities of ECSHIP2D/+
Next, we sought to validate and generalize the mechanistic
data from our murine model, using a complementary system
Figure 3—Insulin resistance in ECSHIP2D/+ mice during hyperinsulinemic-euglycemic clamping. A: Reduced insulin infusion rate (i.e., GIR) in
ECSHIP2D/+ indicative of insulin resistance. B: Blunted glucose uptake in muscle and fat from ECSHIP2D/+ mice. C and D: Comparable hepatic
glucose output in ECSHIP2D/+ mice vs. controls (n$4 for all experiments). Con, control; Rg, insulin-mediated glucose metabolic index. *P< 0.05.
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Figure 4—EC insulin signaling and mechanical shear stress signaling are impaired in ECSHIP2D/+ mice. A: The basal abundance of Akt, pAkt
T308, PDK1, pPDK1, Rictor, pRictor, eNOS, and peNOS S1177 were increased in ECSHIP2D/+ ECs exposed to standard culture media (n $4).
B: Insulin-stimulated (150 nm for 10 min) phosphorylation of eNOS, but not Akt, was impaired in ECSHIP2D/+ ECs (n $6). C: Shear
stress induction (10 min) of Akt and eNOS phosphorylation was impaired in ECSHIP2D/+ ECs (n $6). Representative Western blots are shown
above all panels. *P < 0.05.
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in human ECs. We used lentiviral vectors to express SHIP2-
targeting shRNA, or a nontargeting control shRNA, to
knock down SHIP2 in HUVECs, achieving ;75% reduction
in SHIP2 protein versus that in controls (Fig. 7A). As seen in
ECSHIP2D/+ ECs, the knockdown of SHIP2 reduced SHIP2
activity (Fig. 7B) and enhanced superoxide concentrations
(Fig. 7C). We examined potential sources of superoxide and
again demonstrated increased Nox2 NADPH oxidase expression
Figure 5—Impaired aortic vasodilation in ECSHIP2D/+ mice is associated with oxidative stress and reduced NO bioavailability. A: Reduced
insulin-mediated aortic relaxation in ECSHIP2D/+ mice (n $4). B–D: Reduced L-NMMA–induced vasoconstriction in ECSHIP2D/+ mice indicative
of reduced NO bioavailability (n$3). E and F: Subtle impairment of acetylcholine-mediated vasodilation in aortae from ECSHIP2D/+ mice (n$8).
F: No difference in sodium nitroprusside (SNP)–mediated vasodilation in aortic rings from ECSHIP2D/+ mice (n $3). G–K: MnTmPyP blunts
acetylcholine-mediated vasodilation in aortae from ECSHIP2D/+ mice and controls, but the reduction in acetylcholine-mediated vasodilation
is greater in ECSHIP2D/+ mice (n $4). L: Increased aortic hydrogen peroxide generation in ECSHIP2D/+ mice (n $4). ACh, acetylcholine; AU,
arbitrary units; AUC, area under the curve; M, molar. *P < 0.05; **P < 0.005; ***P < 0.005.
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(Fig. 7D); moreover, the excess superoxide seen in SHIP2-
deﬁcient cells was inhibited by Gp91ds-tat (Fig. 7E and F).
Furthermore, in SHIP2 knockdown HUVECs, S473 pAkt
and S1177 peNOS was more abundant (Fig. 7G), and super-
oxide abundancewas reduced by the PI3K inhibitorsWortmannin
and LY294002 (Fig. 7H). These data imply that increased
PI3K signaling drives Nox2-dependent superoxide production
in the context of human EC SHIP2 knockdown.
DISCUSSION
We provide a number of novel ﬁndings pertaining to the
understanding of endothelial SHIP2 signaling and metabolic
disease: 1) EC-speciﬁc reduction of SHIP2 activity is not
associated with developmental defects; 2) mice with
EC-speciﬁc reduction of SHIP2 activity develop insulin re-
sistance in skeletal muscle and fat, which is not associated
with evidence of inﬂammation; 3) EC-speciﬁc reduction of
SHIP2 activity is associated with endothelial dysfunction,
excess superoxide abundance, and reduced NO bioavailabil-
ity; and 4) oxidative stress associated with SHIP2 knock-
down in murine and human ECs is caused by excessive PI3K
signaling and is Nox2 NADPH oxidase dependent. Our data
emphasize the detrimental impact of increased PI3K/Akt
signaling on EC function and conﬁrm the key role of SHIP2
in maintaining vascular homeostasis. In particular, they reveal
that increased basal PI3K/Akt signal transduction in ECs is
associated with Nox2-mediated vascular oxidative stress and
paradoxical systemic insulin resistance due to impaired adi-
pose tissue and skeletal muscle glucose uptake. Therefore,
although hyperinsulinemia is an adaptive response to hyper-
glycemia, when sustained this may have detrimental effects
on vascular function and glucose uptake in key metabolic
tissues; this raises important questions about the long-term
risks of therapies that induce sustained insulin signaling.
SHIP2, Insulin Signaling, PI3K, and Akt
The ligand-bound insulin receptor phosphorylates tyrosine
residues on downstream substrates, activating PI3K, which
catalyzes phosphorylation of the 39 position of inositol rings,
generating 39 phosphoinositides including PI(3,4,5)P3 (21).
PI(3,4,5)P3 recruits the serine/threonine kinase Akt to the
cell membrane, facilitating its activation and allowing the
phosphorylation of downstream effectors, including eNOS
(19). Short-term in vivo studies have examined the effect of
Figure 6—ECSHIP2D/+ ECs exhibit PI3K- and Nox2-dependent oxidative stress and reduced NO generation. A: Increased superoxide gener-
ation in ECSHIP2D/+ mice, measured with lucigenin-enhanced chemiluminescence (left: n $10) and dihydroethidium (DHE) ﬂuorescence (right:
n$3). B: Increased Nox2 NADPH oxidase protein (representative Western blot shown above the panel) in ECSHIP2D/+ mice (n$9). C: Increased
superoxide abundance in ECSHIP2D/+ mice is normalized by Gp91ds-tat (n $4). D: Increased superoxide abundance in ECSHIP2D/+ mice is
normalized by the PI3K inhibitors Wortmannin and LY294002 (n $4). E: Insulin-stimulated NO production is impaired in ECs from ECSHIP2D/+
mice (n$5). ROS, reactive oxygen species. AU, arbitrary units; GP-tat, Gp91ds-tat NADPH oxidase 2 inhibitor; WT, Wortmannin; LY, LY294002
PI3K inhibitor. *P < 0.05.
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Figure 7—shRNA knockdown of SHIP2 in HUVECs recapitulates the phenotype of ECSHIP2D/+ ECs. A: SHIP2 shRNA reduced SHIP2 protein by
;75% vs. control shRNA (n = 3; representative Western blot shown above the panel). B: SHIP2 activity is reduced by SHIP2 shRNA (n = 3). C:
Increased superoxide abundance in SHIP2 knockdownHUVECsmeasured by lucigenin-enhanced chemiluminescence (n = 3). D: Increased Nox2 NADPH
oxidase protein in SHIP2 knockdown HUVECs (n = 5; representative Western blot shown above the panel). Suppression of excess superoxide
production in SHIP2 knockdownHUVECs by the NOX2 inhibitor Gp91ds-tat, which wasmeasured with lucigenin-enhanced chemiluminescence (n$3) (E)
and dihydroethidium (DHE) ﬂuorescence (n = 6) (F). G: Increased concentration of S473 pAkt and S1177 peNOS in SHIP2 knockdown HUVECs
(n = 5). H: Suppression of excess superoxide production in SHIP2 knockdownHUVECs by the PI3K inhibitorsWortmannin and LY294002 (n = 5). AU, arbitrary
units; ROS, reactive oxygen species; GP-tat, Gp91ds-tat NADPH oxidase 2 inhibitor; WT, Wortmannin; LY, LY294002 PI3K inhibitor. *P < 0.05.
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SHIP2 modulation on insulin sensitivity in models of type 2
diabetes. Adenoviral expression of a dominant-negative
mutant SHIP2 in the liver of obese hyperglycemic mice re-
stored insulin sensitivity and Akt phosphorylation (22),
whereas the expression of wild-type SHIP2 blunted these
(23). In humans, SHIP2 (Inppl1) polymorphisms are associ-
ated with obesity, type 2 diabetes, and the metabolic syn-
drome (24,25). SHIP2 inhibition has thus been suggested as
an approach for treating insulin-resistant type 2 diabetes
(7). However, the effect of SHIP2 inhibition on speciﬁc
components of the arterial wall is ill deﬁned; our data ques-
tion the potential therapeutic beneﬁt of SHIP2 inhibition,
at least in the endothelium.
Endothelial SHIP2 Inhibition and Glucose Homeostasis
We demonstrated that 10-month-old ECSHIP2D/+ mice were
resistant to insulin-mediated glucose lowering, and the vas-
cular dysfunction caused by chronic SHIP2 inactivation may
underpin these ﬁndings. We found reduced insulin-stimulated
eNOS activation in ECSHIP2D/+ ECs, and endothelial-derived
NO is thought to be crucial for insulin-stimulated glucose
uptake; eNOS-deﬁcient mice are systemically insulin resis-
tant, with reduced insulin-mediated glucose uptake in skeletal
muscle (26,27). Kubota et al. (28) demonstrated impaired
insulin-stimulated glucose disposal in the skeletal muscle of
mice with endothelium-speciﬁc deletion of IRS2 due to im-
paired NO bioavailability. Our data sets are consistent with
this, since ECSHIP2D/+ mice have reduced EC insulin sensi-
tivity, diminished insulin-stimulated glucose uptake to skel-
etal muscle, and reduced endothelial NO generation.
However, mice with endothelium-speciﬁc insulin receptor
deletion have normal glucose disposal during clamping
studies (29), suggesting a complex association between vas-
cular insulin signaling and systemic glucose homeostasis.
Importantly, ECSHIP2D/+ mice had preserved proximal in-
sulin signaling, implying that downstream signaling may be
more important in vascular homeostasis, including the reg-
ulation of systemic glucose metabolism.
Endothelial SHIP2 Inhibition, Superoxide Generation,
and eNOS Inhibition
We demonstrate that EC-speciﬁc inactivation of SHIP2 in-
creases basal activation of the PI3K/Akt/eNOS signaling cas-
cade, with potentially important increases in both the total and
phosphorylated forms of key signaling nodes (which did not
increase in response to insulin), and increases the abundance
Figure 8—Proposed mechanism of endothelial dysfunction associated with SHIP2 knockdown. In contrast with normal physiology (A), reduced
SHIP2 activity (B) results in increased basal PI3K/Akt/eNOS signaling, although NOX2 is also hyperactivated, resulting in oxidative stress and
reduced NO bioavailability.
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of superoxide. This is associated with reduced NO production
in isolated ECs and aortic segments under isometric tension,
indicating endothelial dysfunction. The expression of Nox2
NADPH oxidase was increased in the setting of SHIP2
knockdown, and by using the selective antagonist Gp91ds-tat
we implicated Nox2 as the source of excess superoxide.
Moreover, by normalizing superoxide abundance using two
selective PI3K inhibitors, we also implicated excessive PI3K/
Akt signaling as contributing to oxidative stress. Although a
number of studies have shown a link between excessive Akt
activation and superoxide generation (30,31), none have
identiﬁed the source of excess superoxide. Moreover, the
association between SHIP2 and oxidative stress in vivo is
currently unexplored. Our study is therefore the ﬁrst to mech-
anistically link SHIP2 inactivation to increased Nox2 NADPH
oxidase activity, oxidative stress, and endothelial dysfunction
(Fig. 8). By recapitulating these data in human ECs after
silencing SHIP2, we provide support for the relevance of
our in vivo observations to human pathophysiology, sug-
gesting that caution is warranted in the clinical translation
of SHIP2 inhibition. Importantly, we have also published
(12) that mice with endothelial overexpression of the in-
sulin receptor exhibit many of the phenotypic traits noted
in ECSHIP2D/+ mice, including PI3K- and Nox2-dependent
vascular oxidative stress and endothelial dysfunction. In
conjunction, these data suggest that unrestrained signaling
at multiple nodes in the proximal insulin signaling cascade
cause vascular dysfunction mediated by Nox2-dependent
oxidative stress.
Conclusion
Vascular endothelial SHIP2 activity is required to maintain
normal systemic insulin sensitivity and suppress vascular
oxidative stress and endothelial dysfunction caused by
unrestrained PI3K-Nox2 signaling.
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